Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 02, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,407.3 pence per share.
- Treasury Holdings: 248,072,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,749,348,058 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 17, 2006. The total number of shares held in Treasury increased to 248,072,678 as a result of this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,407.3 pence per share.
- Confirm the updated total voting rights denominator of 5,749,348,058 shares for disclosure threshold calculations.
- Note that the company intends to hold the repurchased shares in Treasury rather than retiring them immediately.